Xintela AB (XINT) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.242x

Based on the latest financial reports, Xintela AB (XINT) has a cash flow conversion efficiency ratio of 0.242x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.74 Million ≈ $-724.90K USD) by net assets (Skr-27.88 Million ≈ $-3.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xintela AB (XINT) balance sheet quality index to measure how much of total assets are equity-financed.

Xintela AB - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Xintela AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check XINT cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Xintela AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xintela AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Chorokbaem Healthcare Co Ltd KO:118000	0.023x
Pearl Gold AG F:02P	N/A
Gold Springs Resource Corp TO:GRC	-0.005x
ESV Inc KQ:223310	-0.381x
MMS Ventures Bhd KLSE:0113	-0.026x
Travis Perkins PLC LSE:TPK	0.110x
Pilulka Lekarny as PR:PINK	N/A
Physitrack PLC ST:PTRK	0.072x

Annual Cash Flow Conversion Efficiency for Xintela AB (2013–2024)

The table below shows the annual cash flow conversion efficiency of Xintela AB from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Xintela AB worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr-5.95 Million ≈ $-640.32K	Skr-40.70 Million ≈ $-4.38 Million	6.841x	+156.41%
2023-12-31	Skr4.38 Million ≈ $471.36K	Skr-53.12 Million ≈ $-5.72 Million	-12.127x	-77.41%
2022-12-31	Skr5.78 Million ≈ $621.70K	Skr-39.49 Million ≈ $-4.25 Million	-6.836x	+37.10%
2021-12-31	Skr3.95 Million ≈ $424.76K	Skr-42.89 Million ≈ $-4.62 Million	-10.867x	-1306.49%
2020-12-31	Skr27.61 Million ≈ $2.97 Million	Skr-21.33 Million ≈ $-2.30 Million	-0.773x	+76.68%
2019-12-31	Skr9.32 Million ≈ $1.00 Million	Skr-30.89 Million ≈ $-3.32 Million	-3.313x	-377.25%
2018-12-31	Skr44.95 Million ≈ $4.84 Million	Skr-31.20 Million ≈ $-3.36 Million	-0.694x	+11.03%
2017-12-31	Skr18.41 Million ≈ $1.98 Million	Skr-14.37 Million ≈ $-1.55 Million	-0.780x	+5.90%
2016-12-31	Skr20.98 Million ≈ $2.26 Million	Skr-17.40 Million ≈ $-1.87 Million	-0.829x	+35.11%
2015-12-31	Skr7.46 Million ≈ $802.92K	Skr-9.54 Million ≈ $-1.03 Million	-1.278x	-193.91%
2014-12-31	Skr9.54 Million ≈ $1.03 Million	Skr-4.15 Million ≈ $-446.50K	-0.435x	+26.64%
2013-12-31	Skr5.08 Million ≈ $546.88K	Skr-3.01 Million ≈ $-324.14K	-0.593x	--

About Xintela AB

ST:XINT Sweden Biotechnology

Market Cap

$14.31 Million

Skr132.93 Million SEK

Market Cap Rank

#26081 Global

#548 in Sweden

Share Price

Skr0.19

Change (1 day)

+0.27%

52-Week Range

Skr0.18 - Skr0.49

All Time High

Skr8.60